Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis
Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving...
Saved in:
Published in | Journal of cachexia, sarcopenia and muscle Vol. 15; no. 3; pp. 975 - 988 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
John Wiley & Sons, Inc
01.06.2024
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2190-5991 2190-6009 2190-6009 |
DOI | 10.1002/jcsm.13466 |
Cover
Loading…
Abstract | Background
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.
Methods
We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.
Results
Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).
Conclusions
In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer. |
---|---|
AbstractList | Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. Methods We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Results Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). Conclusions In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer. Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. We developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6 , and hepatocyte STAT3 male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Pre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6 PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer. BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.MethodsWe developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.ResultsPre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (−13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).ConclusionsIn early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer. Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. Methods We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Results Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). Conclusions In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer. Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.BACKGROUNDPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.We developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6-/-, and hepatocyte STAT3-/- male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.METHODSWe developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6-/-, and hepatocyte STAT3-/- male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.Pre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6-/- PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).RESULTSPre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6-/- PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer.CONCLUSIONSIn early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer. |
Author | Dickie, Jessica Krasnow, Stephanie M. Worley, Beth L. Bartlett, Alexandra Q. Mendez, Heike Eil, Robert Arneson‐Wissink, Paige C. Pelz, Katherine Grossberg, Aaron J. |
AuthorAffiliation | 5 Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland OR USA 1 Brenden‐Colson Center for Pancreatic Care Oregon Health & Science University Portland OR USA 3 Division of Oncological Sciences, Knight Cancer Institute Oregon Health & Science University Portland OR USA 2 Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute Oregon Health & Science University Portland OR USA 4 Department of Radiation Medicine Oregon Health & Science University Portland OR USA |
AuthorAffiliation_xml | – name: 1 Brenden‐Colson Center for Pancreatic Care Oregon Health & Science University Portland OR USA – name: 3 Division of Oncological Sciences, Knight Cancer Institute Oregon Health & Science University Portland OR USA – name: 4 Department of Radiation Medicine Oregon Health & Science University Portland OR USA – name: 2 Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute Oregon Health & Science University Portland OR USA – name: 5 Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland OR USA |
Author_xml | – sequence: 1 givenname: Paige C. orcidid: 0000-0002-2706-9652 surname: Arneson‐Wissink fullname: Arneson‐Wissink, Paige C. organization: Oregon Health & Science University – sequence: 2 givenname: Heike surname: Mendez fullname: Mendez, Heike organization: Oregon Health & Science University – sequence: 3 givenname: Katherine surname: Pelz fullname: Pelz, Katherine organization: Oregon Health & Science University – sequence: 4 givenname: Jessica surname: Dickie fullname: Dickie, Jessica organization: Oregon Health & Science University – sequence: 5 givenname: Alexandra Q. surname: Bartlett fullname: Bartlett, Alexandra Q. organization: Oregon Health & Science University – sequence: 6 givenname: Beth L. surname: Worley fullname: Worley, Beth L. organization: Oregon Health & Science University – sequence: 7 givenname: Stephanie M. surname: Krasnow fullname: Krasnow, Stephanie M. organization: Oregon Health & Science University – sequence: 8 givenname: Robert surname: Eil fullname: Eil, Robert organization: Oregon Health & Science University – sequence: 9 givenname: Aaron J. orcidid: 0000-0003-4690-4948 surname: Grossberg fullname: Grossberg, Aaron J. email: grossber@ohsu.edu organization: Oregon Health & Science University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38632714$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kt1qFDEUgAep2Fp74wPIgDcibM3fJJkrKYvaSsUL9TpkkjPTrLPJmMys9s5HEB_RJzG7sxVbxEBIyPnOxyHnPCwOfPBQFI8xOsUIkRcrk9anmDLO7xVHBNdowRGqD_b3qq7xYXGS0grlxTjmFXpQHFLJKRGYHRU_z2HQozNlcp3XfTlG7ZOdDMRSe1tqM7qNHkMsQzvHTHTD6IL_9f0H3Sf1zneljW4DqQQd--scS6PuoBy0NxF2fpOvWWq0uYJvTpebvNM0DBFSAlt-hjF04CG59Ki43-o-wcn-PC4-vX71cXm-uHz_5mJ5drkwlSR8wTBUjErEK9HIlqNKNhXCBhhoQgw1AgvBCeMaCDKyEZabymohrWXCMFbT4-Ji9tqgV2qIbq3jtQraqd1DiJ3SMZfeg2ryX0kjW6CUMCZYU7XCsrbhhlrOCWTXy9k1TM0arAGfP6u_Jb0d8e5KdWGjMMZVFrJseLY3xPBlgjSqtUsG-l57CFNSFDFMKMN8iz69g67CFHMjthRngvJaykw9-bukP7Xc9D4DaAZMDClFaJVxo972NlfoeoWR2k6Y2k6Y2k1YTnl-J-XG-k8Yz_BX18P1f0j1dvnh3ZzzG_Wa5cA |
CitedBy_id | crossref_primary_10_3390_biomedicines13010210 crossref_primary_10_1186_s12944_024_02368_7 crossref_primary_10_12677_acm_2025_153803 crossref_primary_10_1097_CEJ_0000000000000918 crossref_primary_10_1016_j_tem_2024_12_005 |
Cites_doi | 10.1152/ajpendo.00039.2012 10.1038/s41586-018-0235-7 10.1016/S1470-2045(10)70218-7 10.1016/j.pan.2018.11.002 10.1016/j.cmet.2023.05.008 10.3945/ajcn.2008.27273 10.1093/annonc/mdx369.158 10.1016/j.semcdb.2016.02.009 10.1093/ajcn/71.2.583 10.1002/jcsm.12899 10.1038/nrclinonc.2012.209 10.1111/febs.13709 10.3390/nu13093202 10.1056/NEJM197003192821209 10.1038/s41416-021-01301-4 10.1016/j.ccr.2005.04.023 10.1002/jcsm.12225 10.3389/fonc.2022.903157 10.1016/j.cmet.2015.09.005 10.1038/nm980 10.1007/s13539-012-0099-x 10.15430/JCP.2017.22.3.127 10.1042/bj1980227 10.1038/s41586-019-1004-y 10.1016/j.cmet.2016.10.010 10.1084/jem.20190450 10.1093/ajcn/nqy170 10.1002/jcsm.12554 10.1038/s41467-021-22361-3 10.1152/ajpregu.00716.2007 10.1016/j.celrep.2019.07.016 10.1186/s13395-020-00225-6 10.1002/jcsm.12377 10.1073/pnas.1714703115 10.3390/nu14071410 10.1172/JCI82204 10.1096/fj.13-230375 10.1001/jamaoncol.2015.6339 |
ContentType | Journal Article |
Copyright | 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1002/jcsm.13466 |
DatabaseName | Wiley Online Library Open Access (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Impaired ketogenesis drives early pancreatic cancer cachexia |
EISSN | 2190-6009 |
EndPage | 988 |
ExternalDocumentID | oai_doaj_org_article_b7148c8fe3324474b5f7d4fb6c3d662e PMC11154744 38632714 10_1002_jcsm_13466 JCSM13466 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Oregon Health and Science University funderid: P30 CA069533; P30 CA069533 13S5 – fundername: Oregon Pancreas Tissue Registry – fundername: National Cancer Institute funderid: K08CA245188; R37CA280692; R01CA264133 – fundername: Brenden‐Colson Center for Pancreatic Care – fundername: NCI NIH HHS grantid: R37CA280692 – fundername: NCI NIH HHS grantid: R37 CA280692 – fundername: Brenden-Colson Center for Pancreatic Care – fundername: NCI NIH HHS grantid: K08 CA245188 – fundername: NCI NIH HHS grantid: R01CA264133 – fundername: NCI NIH HHS grantid: P30 CA069533 – fundername: Oregon Health and Science University grantid: P30 CA069533 13S5 – fundername: NCI NIH HHS grantid: K08CA245188 – fundername: NCI NIH HHS grantid: R01 CA264133 |
GroupedDBID | --- 0R~ 1OC 24P 2VQ 4.4 40G 53G 5VS 7X7 8FI 8FJ AAFWJ AAKDD AAMMB AAZKR ABUWG ACCMX ACXQS ADBBV ADKYN ADRAZ ADZMN AEFGJ AENEX AFKRA AFPKN AGXDD AHBYD AHSBF AIDQK AIDYY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU AZFZN BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH ITC KQ8 M48 O9- OK1 PHGZM PHGZT PIMPY PQQKQ PROAC RPM RSV SMD SOJ U2A UKHRP ZOVNA AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION ADINQ ADPDF CGR CUY CVF ECM EIF M~E NPM OVD OVEED WIN 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c5826-41e54380657b8f6058b501ce4ea22c3c71776246ae20c8b7d6c5da78dd47c4493 |
IEDL.DBID | 7X7 |
ISSN | 2190-5991 2190-6009 |
IngestDate | Wed Aug 27 01:24:32 EDT 2025 Thu Aug 21 18:33:48 EDT 2025 Thu Jul 10 19:12:29 EDT 2025 Fri Jul 25 07:53:27 EDT 2025 Wed Feb 19 01:58:36 EST 2025 Tue Jul 01 02:51:36 EDT 2025 Thu Apr 24 23:06:05 EDT 2025 Sun Jul 06 04:45:34 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | pancreatic cancer interleukin‐6 ketogenesis STAT3 cachexia |
Language | English |
License | Attribution 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5826-41e54380657b8f6058b501ce4ea22c3c71776246ae20c8b7d6c5da78dd47c4493 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-2706-9652 0000-0003-4690-4948 |
OpenAccessLink | https://www.proquest.com/docview/3064736988?pq-origsite=%requestingapplication% |
PMID | 38632714 |
PQID | 3064736988 |
PQPubID | 4370305 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b7148c8fe3324474b5f7d4fb6c3d662e pubmedcentral_primary_oai_pubmedcentral_nih_gov_11154744 proquest_miscellaneous_3041234164 proquest_journals_3064736988 pubmed_primary_38632714 crossref_citationtrail_10_1002_jcsm_13466 crossref_primary_10_1002_jcsm_13466 wiley_primary_10_1002_jcsm_13466_JCSM13466 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2024 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: June 2024 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Heidelberg – name: Hoboken |
PublicationTitle | Journal of cachexia, sarcopenia and muscle |
PublicationTitleAlternate | J Cachexia Sarcopenia Muscle |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2009; 89 2017; 8 2023; 35 2013; 4 2013; 27 2021; 124 2017; 28 2018; 108 2019; 10 2015; 125 1970; 282 2017; 22 2016; 54 2019; 567 2019; 19 2000; 71 2011; 12 2020; 11 2020; 10 2012; 303 2016; 283 2004; 10 2021; 13 2021; 12 2016; 2 2014; 2 2013; 10 2018; 558 2021; 218 2018; 115 2015; 22 1981; 198 2019; 28 2022; 12 2005; 7 2022; 14 2008; 294 2016; 24 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 Chen I (e_1_2_8_13_1) 2017; 28 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_23_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Shukla SK (e_1_2_8_22_1) 2014; 2 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 39723721 - J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13687. doi: 10.1002/jcsm.13687 |
References_xml | – volume: 71 start-page: 583 year: 2000 end-page: 589 article-title: Weight loss and elevated gluconeogenesis from alanine in lung cancer patients publication-title: Am J Clin Nutr – volume: 22 start-page: 789 year: 2015 end-page: 798 article-title: A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits publication-title: Cell Metab – volume: 13 start-page: 3202 year: 2021 article-title: Ketogenic diets in pancreatic cancer and associated cachexia: cellular mechanisms and clinical perspectives publication-title: Nutrients – volume: 4 start-page: 55 year: 2013 end-page: 61 article-title: Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study publication-title: J Cachexia Sarcopenia Muscle – volume: 558 start-page: 600 year: 2018 end-page: 604 article-title: Altered exocrine function can drive adipose wasting in early pancreatic cancer publication-title: Nature – volume: 22 start-page: 127 year: 2017 end-page: 134 article-title: Rationale, feasibility and acceptability of ketogenic diet for cancer treatment publication-title: J Cancer Prev – volume: 10 year: 2020 article-title: A novel transplantable model of lung cancer‐associated tissue loss and disrupted muscle regeneration publication-title: Skeletal Muscle – volume: 125 start-page: 4447 year: 2015 end-page: 4462 article-title: Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver publication-title: J Clin Invest – volume: 303 start-page: E410 year: 2012 end-page: E421 article-title: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL‐6 and in experimental cancer cachexia publication-title: Am J Physiol‐Endocrinol Metab – volume: 283 start-page: 3002 year: 2016 end-page: 3015 article-title: The JAK/STAT pathway in obesity and diabetes publication-title: FEBS J – volume: 24 start-page: 672 year: 2016 end-page: 684 article-title: Tumor‐induced IL‐6 reprograms host metabolism to suppress anti‐tumor immunity publication-title: Cell Metab – volume: 108 start-page: 857 year: 2018 end-page: 867 article-title: Effects of 3‐hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS‐induced inflammation in humans: anticatabolic impact of ketone bodies publication-title: Am J Clin Nutr – volume: 12 start-page: 2259 year: 2021 end-page: 2261 article-title: Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021 publication-title: J Cachexia Sarcopenia Muscle – volume: 28 year: 2017 article-title: PACTO: a single center, randomized, phase II study of the combination of nab‐paclitaxel and gemcitabine with or without tocilizumab, an IL‐6R inhibitor, as first‐line treatment in patients with locally advanced or metastatic pancreatic cancer publication-title: Ann Oncol – volume: 89 start-page: 1173 year: 2009 end-page: 1179 article-title: A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole‐body energy demands publication-title: Am J Clin Nutr – volume: 12 start-page: 489 year: 2011 end-page: 495 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol – volume: 115 start-page: E743 year: 2018 end-page: E752 article-title: Fenofibrate prevents skeletal muscle loss in mice with lung cancer publication-title: Proc Natl Acad Sci – volume: 282 start-page: 668 year: 1970 end-page: 675 article-title: Starvation in man publication-title: N Engl J Med – volume: 2 start-page: 782 year: 2016 end-page: 789 article-title: Association of body composition with survival and locoregional control of radiotherapy‐treated head and neck squamous cell carcinoma publication-title: JAMA Oncol – volume: 10 start-page: 168 year: 2004 end-page: 174 article-title: Role of STAT‐3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo publication-title: Nat Med – volume: 11 start-page: 973 year: 2020 end-page: 996 article-title: Ketone bodies attenuate wasting in models of atrophy publication-title: J Cachexia Sarcopenia Muscle – volume: 28 start-page: 1612 year: 2019 end-page: 1622.e4 article-title: Modeling human cancer‐induced cachexia publication-title: Cell Rep – volume: 124 start-page: 1623 year: 2021 end-page: 1636 article-title: Pancreatic cancer cachexia: three dimensions of a complex syndrome publication-title: Br J Cancer – volume: 294 start-page: R393 year: 2008 end-page: R401 article-title: Interleukin‐6 and cachexia in mice publication-title: Am J Physiol Regul Integr Comp Physiol – volume: 567 start-page: 249 year: 2019 end-page: 252 article-title: Hepatocytes direct the formation of a pro‐metastatic niche in the liver publication-title: Nature – volume: 198 start-page: 227 year: 1981 end-page: 230 article-title: Effects of liver damage on ketone‐body production and nitrogen balance in starved rats publication-title: Biochem J – volume: 19 start-page: 80 year: 2019 end-page: 87 article-title: Circulating interleukin‐6 is associated with disease progression, but not cachexia in pancreatic cancer publication-title: Pancreatology – volume: 12 year: 2021 article-title: Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia publication-title: Nat Commun – volume: 8 start-page: 824 year: 2017 end-page: 838 article-title: Establishment and characterization of a novel murine model of pancreatic cancer cachexia publication-title: J Cachexia Sarcopenia Muscle – volume: 35 year: 2023 article-title: Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia publication-title: Cell Metab – volume: 2 start-page: 1 year: 2014 end-page: 19 article-title: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia publication-title: Cancer Metab – volume: 10 start-page: 90 year: 2013 end-page: 99 article-title: Understanding the mechanisms and treatment options in cancer cachexia publication-title: Nat Rev Clin Oncol – volume: 14 start-page: 1410 year: 2022 article-title: The influence of ketone bodies on circadian processes regarding appetite, sleep and hormone release: a systematic review of the literature publication-title: Nutrients – volume: 218 year: 2021 article-title: Tumor‐derived IL‐6 and trans‐signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia publication-title: J Exp Med – volume: 27 start-page: 3572 year: 2013 end-page: 3582 article-title: Cancer‐ and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle publication-title: FASEB J – volume: 7 start-page: 469 year: 2005 end-page: 483 article-title: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice publication-title: Cancer Cell – volume: 10 start-page: 378 year: 2019 end-page: 390 article-title: MyD88 signalling is critical in the development of pancreatic cancer cachexia publication-title: J Cachexia Sarcopenia Muscle – volume: 12 start-page: 12 year: 2022 article-title: Systemic ketone replacement does not improve survival or cancer cachexia in mice with lung cancer publication-title: Front Oncol – volume: 54 start-page: 28 year: 2016 end-page: 41 article-title: STAT3 in the systemic inflammation of cancer cachexia publication-title: Semin Cell Dev Biol – ident: e_1_2_8_10_1 doi: 10.1152/ajpendo.00039.2012 – ident: e_1_2_8_20_1 doi: 10.1038/s41586-018-0235-7 – ident: e_1_2_8_7_1 doi: 10.1016/S1470-2045(10)70218-7 – ident: e_1_2_8_8_1 doi: 10.1016/j.pan.2018.11.002 – ident: e_1_2_8_35_1 doi: 10.1016/j.cmet.2023.05.008 – ident: e_1_2_8_26_1 doi: 10.3945/ajcn.2008.27273 – volume: 28 year: 2017 ident: e_1_2_8_13_1 article-title: PACTO: a single center, randomized, phase II study of the combination of nab‐paclitaxel and gemcitabine with or without tocilizumab, an IL‐6R inhibitor, as first‐line treatment in patients with locally advanced or metastatic pancreatic cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdx369.158 – ident: e_1_2_8_39_1 doi: 10.1016/j.semcdb.2016.02.009 – ident: e_1_2_8_31_1 doi: 10.1093/ajcn/71.2.583 – ident: e_1_2_8_40_1 doi: 10.1002/jcsm.12899 – ident: e_1_2_8_2_1 doi: 10.1038/nrclinonc.2012.209 – ident: e_1_2_8_33_1 doi: 10.1111/febs.13709 – ident: e_1_2_8_37_1 doi: 10.3390/nu13093202 – ident: e_1_2_8_4_1 doi: 10.1056/NEJM197003192821209 – ident: e_1_2_8_6_1 doi: 10.1038/s41416-021-01301-4 – ident: e_1_2_8_24_1 doi: 10.1016/j.ccr.2005.04.023 – ident: e_1_2_8_16_1 doi: 10.1002/jcsm.12225 – volume: 2 start-page: 1 year: 2014 ident: e_1_2_8_22_1 article-title: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia publication-title: Cancer Metab – ident: e_1_2_8_17_1 doi: 10.3389/fonc.2022.903157 – ident: e_1_2_8_29_1 doi: 10.1016/j.cmet.2015.09.005 – ident: e_1_2_8_32_1 doi: 10.1038/nm980 – ident: e_1_2_8_5_1 doi: 10.1007/s13539-012-0099-x – ident: e_1_2_8_38_1 doi: 10.15430/JCP.2017.22.3.127 – ident: e_1_2_8_21_1 doi: 10.1042/bj1980227 – ident: e_1_2_8_28_1 doi: 10.1038/s41586-019-1004-y – ident: e_1_2_8_12_1 doi: 10.1016/j.cmet.2016.10.010 – ident: e_1_2_8_11_1 doi: 10.1084/jem.20190450 – ident: e_1_2_8_34_1 doi: 10.1093/ajcn/nqy170 – ident: e_1_2_8_36_1 doi: 10.1002/jcsm.12554 – ident: e_1_2_8_3_1 doi: 10.1038/s41467-021-22361-3 – ident: e_1_2_8_9_1 doi: 10.1152/ajpregu.00716.2007 – ident: e_1_2_8_14_1 doi: 10.1016/j.celrep.2019.07.016 – ident: e_1_2_8_15_1 doi: 10.1186/s13395-020-00225-6 – ident: e_1_2_8_19_1 doi: 10.1002/jcsm.12377 – ident: e_1_2_8_23_1 doi: 10.1073/pnas.1714703115 – ident: e_1_2_8_30_1 doi: 10.3390/nu14071410 – ident: e_1_2_8_27_1 doi: 10.1172/JCI82204 – ident: e_1_2_8_18_1 doi: 10.1096/fj.13-230375 – ident: e_1_2_8_25_1 doi: 10.1001/jamaoncol.2015.6339 – reference: 39723721 - J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13687. doi: 10.1002/jcsm.13687 |
SSID | ssj0000461650 |
Score | 2.364833 |
Snippet | Background
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life... Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and... BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life... Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both... |
SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 975 |
SubjectTerms | Animals Body fat cachexia Cachexia - etiology Cachexia - metabolism Cell Line, Tumor Diet, Ketogenic Disease Models, Animal Female Food Glucose Humans Immunoassay interleukin‐6 ketogenesis Ketone Bodies - metabolism Laboratory animals Liver Liver - metabolism Magnetic resonance imaging Male Metabolism Mice Musculoskeletal system Nutrition research Original Pancreatic cancer Pancreatic Neoplasms - complications Pancreatic Neoplasms - metabolism Plasma Signal Transduction STAT3 STAT3 Transcription Factor - metabolism |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJvAgozgAlLYxM_kCCtW1UrlAivtLfJjspRHuupjxZGfgPiJ_BJmnDS0YgUXDlWqeqI4nvHMN_X4M2PPUM3eRx_zFnyRK1eK3EWrcmilqIV2hfb0h_70rZmcqONTfbp11BfVhPX0wP3AHXiLgD1ULUgM_coqr1sbVetNkNEYAeR9MeZtJVPJBytTmnQ8q6C90hpR0MhNKg4-huWXl6VUiRrxdzRKpP2XIc0_Cya3gWyKREc32PUBQvJXfddvsivQ3WJXp8Mi-W32YwJUJh041Wag4IrCUUQVLrjrIqedDBeUavN527dtHMfPb9_lcBNtUudxQZy0HIgDGdsQR54BR-_RA83AA1nMAi-o-K8zxy_ws1yfp9JaiPwTrOZn5Epnyzvs5OjN-8NJPhy9kAeNCUeuStDERW-09VVLS6deF2UABU6IIAMmgehFlXEgilB5G03Q0dkqRmWDUrW8y_a6eQf3GY8W3Qa0UBkVVB1jLRFBgsCxdK6tiyJjzzcqaMLAS07HY3xuekZl0ZC6mqSujD0dZc97No5LpV6TJkcJYtBOP6BdNYNdNf-yq4ztb-ygGab1sqF0zUpTV1XGnozNOCFplcV1MF-TjEI0gDhXZexebzZjT2RlpMAHZ6zaMaidru62dLMPifS7JN4kq_DWF8n2_vL-zfHhu2n69uB_jMRDdk0gkuvr4_bZ3mqxhkeIxFb-cZp0vwB9SzV3 priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF6VIiEuiDeGghbBBSQXe5_2ASGoqKJK4QKRerP25RAodnGSqvwJfjMzaztqRNSDFSs7q9g7j_0mu_sNIa9BzdZ669M62CwVJmep8VqkoeasZNJk0uIf-tMvajITJ6fydI-M9TuHAVzuTO2wntSsOzu8_P3nAzj8-4FA9N0Pt_x1mHOh1A1yE2YkjQ46HWB-jMhC5SoWa2V4cloCJtowlV7tvjU3RQr_Xbjz_-2TV2FtnJeO75I7A6CkH3sLuEf2QnOf3JoOS-YPyN9JwE3TjuJODRBc4eTkQaEdNY2neK7hAhNv2tZ92xhGUj50wQPr1HfIT0sD8iGngCjngUIc6SGnow5tp4MPMIHLhaEXcC3X53GTbfD0Z1i1cwyqi-VDMjv-_O1okg5FGFInIfVIRR4kstIrqW1R4yKqlVnuggiGMccdpIMQT4UygWWusNorJ73RhfdCOyFK_ojsN20TnhDqNQSQUIdCCSdK70sOWDIwGEdj6jLLEvJmHP7KDQzlWCjjrOq5lVmFqqqiqhLyaiN73vNy7JT6hFrcSCCXdvyi7ebV4JqV1ZASuqIOHMCl0MLKWntRW-W4V4qFhByMNlCN9llh4qa5KosiIS83zeCauN5imtCuUUYALgDEKxLyuDeZzZPwQnEGP5yQYsuYth51u6VZfI_03zkyKGkBXd9Gu7vm_auTo6_TePf0-pd4Rm4zQGv9HrgDsr_q1uE5oK2VfRFd6R8ydyty priority: 102 providerName: Scholars Portal – databaseName: Wiley Online Library Open Access (WRLC) dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9RAEG7WFcSL-Da6SoteFOIm_UzAiy4uw8KIoAt7C_3KOD6SJZlZPPoTxJ_oL7Gqk8k6uAgehgzT1SST6qr-qrvqa0Kegpqt9dandbBZKkzOUuO1SEPNWcmkyaTFBf35WzU7Fkcn8mSHvNzUwgz8ENOCG1pG9Ndo4Mb2--ekoZ9c__VFzoVSl8hlrK1F5nwm3k0rLEglruIRrQzrpSUgoYmflO2fd9-akSJx_0Vo8--kyT_BbJyNDq-TayOMpK8Gvd8gO6G5Sa7Mx43yW-TnLGCqtKOYnwGCK5ySPKixo6bxFKsZzjDcpm09tG2cx6_vP_jYCQvVqe-Ql5YG5EGGNsCSi0DBgwxg01GHo6aDCyj_29LQM_j069OYXhs8_RxW7QLd6bK_TY4P33w4mKXj8QupkxB0pCIPEvnoldS2qHH71Mosd0EEw5jjDgJB8KRCmcAyV1jtlZPe6MJ7oZ0QJb9Ddpu2CfcI9RpcR6hDoYQTpfclBxQZGLxLY-oyyxLybKOCyo3c5HhExpdqYFVmFaqriupKyJNJ9nRg5LhQ6jVqcpJAFu34Q9stqtEoK6shGHRFHTjASqGFlbX2orbKca8UCwnZ24yDajTtvsKQTXNVFkVCHk_NYJS402Ka0K5RRgAiAKwrEnJ3GDbTk_BCcQY3TkixNaC2HnW7pVl-jMTfOXInaQFdn8ex94__Xx0dvJ_Hb_f_R_gBucoAtQ25cHtkd9Wtw0NAXSv7KBrXb5ipLgQ priority: 102 providerName: Wiley-Blackwell |
Title | Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.13466 https://www.ncbi.nlm.nih.gov/pubmed/38632714 https://www.proquest.com/docview/3064736988 https://www.proquest.com/docview/3041234164 https://pubmed.ncbi.nlm.nih.gov/PMC11154744 https://doaj.org/article/b7148c8fe3324474b5f7d4fb6c3d662e |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJiFeEN8ERmUELyCFpbZjJ0-ITZuqSZ0mYFLfIn-lKx9JSdqJv4K_mTsnzaiY9tC0ii9qkjuffz6ff0fIW1CzMc64uPQmiYUes1g7JWJfcpazVCepwYD-9ExOLsTpLJ31Abe2T6vc-MTgqF1tMUZ-gEhZcZln2cflrxirRuHqal9CY4fsIXUZpnSpmRpiLEgmLkORVoY7plPAQgNDKTv4ZtufH8ZcBILE6zEpUPffhDf_T5v8F86G8ejkAbnfA0n6qdP8Q3LHV4_I3Wm_VP6Y_Jl4TJa2FDM0QHCFg5IDRTZUV47ifoYrnHDTuuzaNu4j5v0luFGdugZ5aalHHuQYkOTcU_AfHdS01KLNNPAFqv-90PQKPu16GZJrvaPf_aqeozNdtE_Ixcnx16NJ3BdfiG0KU45YjH2KbPQyVSYrcfHUpMnYeuE1Y5ZbmAaCHxVSe5bYzCgnbeq0ypwTygqR86dkt6or_5xQp8Bx-NJnUliRO5dzwJCewXvUusyTJCLvNq-_sD0zORbI-FF0nMqsQFUVQVUReTPILjs-jhulDlGLgwRyaIcTdTMv-i5ZGAVTQZuVngOoFEqYtFROlEZa7qRkPiL7Gxso-o7dFtdmGJHXQzN0SVxn0ZWv1ygjAA8A0hURedaZzHAnPJOcwR9HJNsypq1b3W6pFpeB9nuMzElKwKXvg93d8vzF6dGXafj14vaHeEnuMUBpXe7bPtldNWv_ClDWyozIDhPno9ChRmTv8Pjs_PMoRCzgOBXZXwSzLZQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcCA4yAB5DCUtuJ0weE2NjUXVoh2KS9Bd9SukFSehnwJ_gp_EbOcS6jYtrbHqpWtaNczsnn79jH3yHkOZhZa6ttmDsdhUJ1WaisFKHLOeuxWEWxxgn9wTDpH4rdo_hohfxp9sJgWmWDiR6obWlwjnwdmbLkSS9N306-h1g1CldXmxIalVvsuV8_IGSbvdl5D_Z9wdj21sFmP6yrCoQmBi4diq6LUWY9iaVOc1wV1HHUNU44xZjhBuIbAAiRKMcik2ppExNbJVNrhTRCoPgSQP6q4BDKdMjqxtbww8d2VgflyxNfFpbhHu0Y2FericrWj83s2-suF16S8WwU9MUCzmO4_ydq_kug_Qi4fYNcr6krfVf52k2y4opb5MqgXpy_TX73HaZnG4o5IdBxjsOgBdeZUlVYijsoTjHEp2VetTWAFfL6ENwaT-0UlXCpQ-XlELjryFFArIrcGmrQS6fwBc72c6zoKXxmi4lP53WWnrh5OUL4Hs_ukMNLMcxd0inKwt0n1EqAKpe7NBFG9KztcWCtjsFzVCrvRVFAXjaPPzO1FjqW5PiaVSrOLENTZd5UAXnW9p1UCiDn9tpAK7Y9ULXb_1FOR1kNApmWEHyaNHccaKyQQse5tCLXieE2SZgLyFrjA1kNJbPszPED8rRtBhDAlR1VuHKBfQQwEODWIiD3Kpdpr4SnCWdw4oCkS860dKnLLcX4ixca76JWkxRw6Cvvdxfcf7a7-Wngfz24-CaekKv9g8F-tr8z3HtIrjHgiFXm3RrpzKcL9wg43lw_rl8sSj5f9rv8FywMZc8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ZbtQwFLWqIlW8IHYCBYyAB5BCEy9x5gEhaBlNW6ZCgkrzlsZLplMgGWYp8BN8EF_Hvc5SRlR960M00dhRlnt9fGxfn0vIMzCz1lbbsHA6CkUeszC3SoSu4KzHZB5JjRP6w4NkcCj2RnK0Rv60e2EwrLLFRA_UtjI4R76FTFnxpAcDtqIJi_i4038z_R5iBilcaW3TadQusu9-_YDh2_z17g7Y-jlj_feftwdhk2EgNBJ4dShiJ1FyPZFKpwWuEGoZxcYJlzNmuIGxDoCFSHLHIpNqZRMjba5Sa4UyQqAQE8D_FcVljG1MjVQ3v4NC5olPEMtwt7YEHtapo7KtEzP_9irmwosznvWHPm3AeVz3_5DNf6m07wv718m1hsTSt7XX3SBrrrxJNobNMv0t8nvgMFDbUIwOgYoL7BAtONGM5qWluJfiFAf7tCrqsha6Qt5cgpvkqZ2hJi51qMEcAosdOwrYVdNcQw366wx-wO1-TnJ6Csd8OfWBvc7SL25RjRHIJ_Pb5PBSzHKHrJdV6e4RahWAlitcmggjetb2OPBXx-A75nnRi6KAvGg_f2YaVXRMzvE1q_WcWYamyrypAvK0qzuttUDOrfUOrdjVQP1u_0c1G2cNHGRawTDUpIXjQGiFEloWyopCJ4bbJGEuIJutD2QNqMyzsyYQkCddMcABrvHkpauWWEcAFwGWLQJyt3aZ7kl4mnAGNw5IuuJMK4-6WlJOjr3keIyqTUrApS-9313w_tne9qehP7t_8Us8JhvQgrMPuwf7D8hVBmSxDsHbJOuL2dI9BLK30I98q6Lk6LKb8V_AVWif |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatic+signal+transducer+and+activator+of+transcription-3+signalling+drives+early-stage+pancreatic+cancer+cachexia+via+suppressed+ketogenesis&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Arneson-Wissink%2C+Paige+C&rft.au=Mendez%2C+Heike&rft.au=Pelz%2C+Katherine&rft.au=Dickie%2C+Jessica&rft.date=2024-06-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2190-5991&rft.eissn=2190-6009&rft.volume=15&rft.issue=3&rft.spage=975&rft.epage=988&rft_id=info:doi/10.1002%2Fjcsm.13466&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon |